TissueLabs
TissueLabs is a Swiss biotechnology company based in Bellinzona.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
TissueLabs is a Swiss biotechnology company based in Bellinzona. The company focuses on tissue engineering and biofabrication and develops 3D bioprinters and tissue-specific biomaterials for use in laboratory research applications including drug testing, disease modeling and cell culture.
History
TissueLabs was founded in January 20191 in Brazil by Gabriel Liguori and Emerson Moretto. The company originated in the IPEN-Cietec incubator at the University of São Paulo and raised approximately $1.6 million in seed funding during its initial phase of development. In 2021, the company relocated its headquarters to Switzerland, initially based in Manno before moving to Bellinzona.
Early development
During its early development, TissueLabs focused on laboratory tools for tissue engineering research. In 2019, the company introduced MatriXpec, a line of tissue-specific hydrogels derived from decellularized extracellular matrix, developed for use in three-dimensional cell culture and bioprinting.
By 2020, formulations had been developed for tissue types including myocardium, lung, liver, kidney, skin, and cartilage. In 2020, TissueLabs introduced TissueStart, an extrusion-based 3D bioprinter designed for academic and laboratory use.
In early 2020, during the COVID-19 pandemic, it developed MatriWell, an in vitro system combining a cell culture insert with lung-derived hydrogels to model aspects of lung epithelium. The system was made for research use in studies of SARS-CoV-2 infection in pulmonary cells.
MatriWell was also used in a 2023 peer-reviewed research examining three-dimensional models for respiratory disease investigation.
Growth
In 2021, TissueLabs introduced TissueRay, an MSLA-based 3D bioprinter. The system was presented at the 6th Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress. In 2023, the company closed a pre-seed financing round of $800,000, led by Mergus Ventures, with participation from MIT Angels and others.
The funds supported the establishment of a new biofabrication facility in Bellinzona, which began operations in early 2024. Initially based in Manno, the relocation to Bellinzona was related to being closer to European biotech and research networks.
In 2024, TissueLabs was selected to participate in the Venture Leaders Biotech program, a Swiss initiative supporting early-stage biotechnology companies. In 2025, TissueLabs introduced TissuePro, a 3D bioprinter with five independent extrusion heads designed for more complex tissue engineering applications.
It was also included in the Top 100 Startups to Watch list published by Pequenas Empresas & Grandes Negócios (PEGN) that year.
External links
Official website
Text derived from https://en.wikipedia.org/w/index.php?oldid=1379008583 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “TissueLabs” date of foundation (×1) · confidence 0.95 revision URL